Capecitabine: a review.

By C. Walko, C. Lindley. Clinical Therapeutics, 2005

684 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Oncology

View Paper: https://www.semanticscholar.org/paper/647c2a0ebdafaff0d0f55cde94c9b48bb5e17b68

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. N. Nagarsheth
2. W. Zou
3. Lieping Chen

Citations in the corpus

• Prodrugs: design and clinical applications (2008, background): “A need for reduced normal tissue exposure of the cytotoxic drug, 5-fluorouracil (5-FU), has led to the development of a prodrug that is activated by tumour-selective enzyme”
• Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy (2017, background): “In general, active cytotoxic drugs, including 5-fluorouracil (5-FU) and capecitabine, inhibit the enzyme activity of thymidylate synthase during 548 Cell 170, 548–563, July 27, 2017 ª 2017 Elsevier Inc. DNA replication (Walko and Lindley, 2005).”